Cr9.Ax

CR9.AX has a market price of $0.012 and a market cap of $16,605,880.94, indicating a relatively small capitalization. The company's price-to-book ratio is 5.42, suggesting that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio is negative at -18.01, reflecting the company's current unprofitability.

In terms of profitability, CR9.AX reported a net income of -$908,010 and an operating income of -$922,720, indicating significant losses. The return on equity is -29.66%, and the return on assets is -24.18%, both of which are well below industry norms and suggest poor capital efficiency and asset utilization.

The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with the company's revenue streams. The operating cash flow is negative at -$854,260, and the capital expenditure is -$197,220, indicating that the company is not generating sufficient cash to fund its operations and investments.

Looking at the growth trajectory, CR9.AX has not provided specific numeric deltas for the current or next fiscal year. However, the company's negative operating and net income suggest a challenging outlook. The company's liquidity is rated as medium, and the dilution risk is low, but the negative net cash position after subtracting total debt is a key flag.

Recent events and filings do not provide specific details on the company's strategic direction or operational changes. The company's financial health is further complicated by its high debt-to-equity ratio of 0.0, which indicates a lack of leverage but also a potential constraint on growth.

The company's recent financial performance and risk profile suggest a need for significant operational improvements and strategic adjustments to address its current financial challenges. The lack of profitability and negative cash flows highlight the urgency of these actions.